These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 25758751)

  • 1. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
    Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
    J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic interventions for combating Parkinson's disease and prospects of Nose-to-Brain drug delivery.
    Ahmad J; Haider N; Khan MA; Md S; Alhakamy NA; Ghoneim MM; Alshehri S; Sarim Imam S; Ahmad MZ; Mishra A
    Biochem Pharmacol; 2022 Jan; 195():114849. PubMed ID: 34808125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
    Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
    Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson's disease treatment?
    Rehman S; Nabi B; Zafar A; Baboota S; Ali J
    Expert Opin Drug Deliv; 2019 Dec; 16(12):1355-1366. PubMed ID: 31663382
    [No Abstract]   [Full Text] [Related]  

  • 5. Micro- and nanotechnology approaches to improve Parkinson's disease therapy.
    Torres-Ortega PV; Saludas L; Hanafy AS; Garbayo E; Blanco-Prieto MJ
    J Control Release; 2019 Feb; 295():201-213. PubMed ID: 30579984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
    Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
    Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration.
    Wen Z; Yan Z; Hu K; Pang Z; Cheng X; Guo L; Zhang Q; Jiang X; Fang L; Lai R
    J Control Release; 2011 Apr; 151(2):131-8. PubMed ID: 21362449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoneurotherapeutics approach intended for direct nose to brain delivery.
    Md S; Mustafa G; Baboota S; Ali J
    Drug Dev Ind Pharm; 2015; 41(12):1922-34. PubMed ID: 26057769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method.
    Md S; Haque S; Fazil M; Kumar M; Baboota S; Sahni JK; Ali J
    Expert Opin Drug Deliv; 2014 Jun; 11(6):827-42. PubMed ID: 24655115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
    Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa delivery systems: advancements in delivery of the gold standard.
    Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
    Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity.
    Raj R; Wairkar S; Sridhar V; Gaud R
    Int J Biol Macromol; 2018 Apr; 109():27-35. PubMed ID: 29247729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.
    Aly AE; Waszczak BL
    Expert Opin Drug Deliv; 2015; 12(12):1923-41. PubMed ID: 26289676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nose-to-brain peptide delivery - The potential of nanotechnology.
    Samaridou E; Alonso MJ
    Bioorg Med Chem; 2018 Jun; 26(10):2888-2905. PubMed ID: 29170026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson's disease.
    Tang S; Wang A; Yan X; Chu L; Yang X; Song Y; Sun K; Yu X; Liu R; Wu Z; Xue P
    Drug Deliv; 2019 Dec; 26(1):700-707. PubMed ID: 31290705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the Role of Nanoparticle-based Treatment for Parkinson's Disease.
    Moni MMR; Begum MM; Uddin MS; Ashraf GM
    Curr Drug Metab; 2021; 22(7):550-560. PubMed ID: 33530903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into direct nose to brain delivery: current status and future perspective.
    Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.
    Gunay MS; Ozer AY; Chalon S
    Curr Neuropharmacol; 2016; 14(4):376-91. PubMed ID: 26714584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy.
    Khatri DK; Preeti K; Tonape S; Bhattacharjee S; Patel M; Shah S; Singh PK; Srivastava S; Gugulothu D; Vora L; Singh SB
    Curr Neuropharmacol; 2023; 21(3):493-516. PubMed ID: 35524671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.